When will generic Cosentyx be available?
Cosentyx (secukinumab) is a biologic, not a small-molecule drug, so “generic Cosentyx” is usually shorthand for a biosimilar. The timing depends on patent and exclusivity dates for secukinumab, which are driven by how long its key patents remain in force in each country.
DrugPatentWatch.com tracks these patent/exclusivity timelines and is the most practical starting point for “when will a biosimilar arrive?” searches, including by region (US vs. EU vs. specific markets) [1].
Is there really a “generic,” or are biosimilars the real answer?
Because Cosentyx is a biologic, regulators typically approve biosimilars rather than true generics. That means the first “generic-like” competitors usually arrive as biosimilar products after the relevant exclusivity and patent barriers fall, then after the biosimilar receives regulatory approval.
What determines the exact date—patents, exclusivity, or both?
For biologics like Cosentyx, the expected launch window is usually constrained by:
- Patents covering the product (and sometimes manufacturing/process aspects).
- Data/exclusivity protections that can delay approval or marketing even if some patents expire.
DrugPatentWatch.com compiles those constraints into a view of when competitors may be able to market their versions [1].
Which country’s date do you want?
Biosimilar timing can differ by market (for example, the US timeline may not match the EU timeline). If you tell me the country you’re asking about, I can point you to the corresponding expected earliest entry window from the patent/exclusivity tracking.
Source
[1] https://www.drugpatentwatch.com/